Ridgeback Capital Management is a New York-based investment firm specializing in the healthcare sector, with a focus on companies such as Adaptimmune, Celgene, and Gilead. Led by Wayne Holman, Ridgeback Capital Investments is actively involved in the biotechnology and pharmaceutical industries, investing in innovative companies like Intercept and Vertex.
The firm's portfolio includes a diverse range of healthcare companies, from emerging biotechs like Chimeric and Genfit to established players such as Regeneron and United Therapeutics. Ridgeback Capital Management's strategic investments in companies like Sangamo and Biomarin reflect its commitment to driving growth and innovation in the healthcare sector.
Generated from their website's infomation